Innovation through M&A in the biopharmaceutical sector

Dr Arsia Amir-Aslani is Program Director at Department of Management and Technology, Grenoble EM, Grenoble, France. He is the Program Director of the advanced master’s degree “Biotechnology and Pharmaceutical Management” at Grenoble Ecole de Management. He is a former Investment Banker and was a Senior Marketing Executive at a healthcare consultancy firm, where he provided consulting services to leading healthcare companies. He has more than 18 years of experience in the hi-technology and biotechnology sectors from a capital market, consulting, educational and industry perspective. He holds a PhD in biochemical sciences from the University of Paris, Pierre et Marie-Curie, as well as an MSc in international management from the University of Paris, Sorbonne. Furthermore, since 2009, he has been a Professor of strategy & finance at Grenoble Ecole de Management. He has numerous publications in both academic and practitioner journals.

Mark Anthony Chanel is Affiliate Professor of Strategy and Finance at Grenoble Graduate School of Business, Grenoble EM, Grenoble, France. He has more than 15 years of professional work experience in healthcare and technology companies, Mark Chanel is currently working as a Consultant helping small and midsized companies, while also teaching at several universities. Most recently, Mark was the Director of finance and administration for a company focused on the pharmaceutical market in the USA, and was also a Director in a medical device company that went through a successful initial public offering on the NASDAQ stock exchange. Mark’s areas of expertise include finance, human resources, operations and competitive intelligence. He holds a BSE in chemical engineering, an MSc in management consulting and an MBA in finance. In addition, he has authored several papers dealing with finance and competitive intelligence.